source
- Argenx to acquire Forte Biosciences for $2.2 billion, adding anti‑CD122 antibody programArgenx announced a $2.2 billion cash transaction to purchase Forte Biosciences, a biotech focused on autoimmune therapies. The acquisition brings Forte's anti‑CD122 monoclonal antibody, which is c…
- Virginia judge orders FDA to revisit Biden-era mifepristone restrictionsA federal judge in Virginia has ruled that the FDA must reexamine certain restrictions on the abortion medication mifepristone that were put in place during the previous administration. The judge…